Internal Medicine, Hematology · Westwood, NJ
NPI
1578596508
Since 2006
Specialty
Internal Medicine, Hematology
Code 207RH0000X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
260 Old Hook Rd, Suite 301
Westwood, NJ, 07675
Phone (201) 383-4840
Groups this clinician bills Medicare through
Medicare paid, 2024
$967K
57,631 services
Medicare patients, 2024
878
Average age 75
Drug cost, 2024
$3.7M
905 prescriptions
Company payments, 2025
$3,573
From 50 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert Tassan was code J1439 (injection, ferric carboxymaltose, 1 mg), 18,000 times for 13 patients. In total Robert Tassan billed 57,631 services in 73 codes, and Medicare paid $967K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 18,000 | 13 | $0.87 | $16K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 7,200 | 59 | $16.02 | $115K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 6,800 | 18 | $6.41 | $44K |
| 99214 Office E&M - Established | Office | 1,862 | 594 | $104.17 | $194K |
| 85025 Blood Count | Office | 1,125 | 371 | $7.60 | $8,551 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 773 | 358 | $13.75 | $11K |
| 96372 Injection Administration | Office | 269 | 37 | $12.14 | $3,266 |
| 99233 Hospital E&M - Subsequent | Facility | 232 | 121 | $98.62 | $23K |
| 99204 Office E&M - New | Office | 183 | 183 | $133.58 | $24K |
| 36415 Venipuncture Blood Collection | Office | 177 | 85 | $8.65 | $1,531 |
| 96365 Intravenous Infusion, Hydration | Office | 153 | 78 | $55.56 | $8,500 |
| 99195 Treatment - Miscellaneous | Office | 107 | 36 | $80.33 | $8,596 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 89 | 14 | $0.92 | $82.32 |
| 99223 Hospital E&M - Initial | Facility | 38 | 37 | $146.39 | $5,563 |
| 99215 Office E&M - Established | Office | 33 | 33 | $140.77 | $4,645 |
By year: 2022 $1.1M for 153,096 services; 2023 $868K for 153,185 services; 2024 $967K for 57,631 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,125 | 371 | $7.60 | $8,551 |
| 36415 Venipuncture Blood Collection | 177 | 85 | $8.65 | $1,531 |
Medicare prescription drug claims, 2024
In 2024, the drug Robert Tassan prescribed most often to Medicare patients was Eliquis (Apixaban), with 178 prescriptions and refills. In total Robert Tassan wrote 905 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 178 | 335 | 52 | $187K |
| Hydroxyurea Generic | 123 | 328 | 40 | $3,539 |
| Imbruvica Ibrutinib | 57 | 57 | Under 11 | $885K |
| Xarelto Rivaroxaban | 54 | 132 | 13 | $74K |
| Deferasirox Generic | 37 | 37 | Under 11 | $4,146 |
| Anastrozole Generic | 27 | 81 | Under 11 | $845 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 25 | 25 | Under 11 | $236 |
| Oxycodone Hcl Generic | 22 | 22 | Under 11 | $176 |
| Promacta Eltrombopag Olamine | 20 | 27 | Under 11 | $356K |
| Warfarin Sodium Generic | 19 | 55 | Under 11 | $213 |
| Gabapentin Generic | 14 | 20 | Under 11 | $225 |
| Azathioprine Generic | 14 | 14 | Under 11 | $243 |
| Jakafi Ruxolitinib Phosphate | 13 | 13 | Under 11 | $199K |
| Lorazepam Generic | 13 | 19 | Under 11 | $102 |
| Givlaari Givosiran Sodium | 13 | 13 | Under 11 | $1.0M |
Brand drugs: - claims; generic drugs: 488 claims; opioid claims: 64.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert Tassan $3,573 ($3,573 in general payments such as food, travel and fees) from 50 companies. The largest payer was Novartis Pharmaceuticals Corporation with $322.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 19 | $322 |
| Daiichi Sankyo Inc. 4568.T | 22 | $285 |
| Abbvie Inc. ABBV | 16 | $270 |
| Rigel Pharmaceuticals, Inc. RIGL | 14 | $247 |
| Incyte Corporation INCY | 13 | $209 |
| E.R. Squibb & Sons, L.L.C. BMY | 13 | $176 |
| Celgene Corporation BMY | 10 | $161 |
| PharmaEssentia USA Corporation 6446.TW | 11 | $154 |
| Karyopharm Therapeutics Inc. KPTI | 8 | $126 |
| Pfizer Inc. PFE | 5 | $113 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.